Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

New statins also produce fatigue: spontaneous reporting as a complementary system to increase safety knowledge--reply.

Golomb BA, Koperski S.

JAMA Intern Med. 2013 Feb 11;173(3):247-8. doi: 10.1001/jamainternmed.2013.2113. No abstract available.

PMID:
23400663
2.

New statins also produce fatigue: spontaneous reporting as a complementary system to increase safety knowledge.

TarapuƩs M, Cereza G, Figueras A.

JAMA Intern Med. 2013 Feb 11;173(3):247-8. doi: 10.1001/jamainternmed.2013.1614. No abstract available.

PMID:
23400662
3.

Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial.

Golomb BA, Evans MA, Dimsdale JE, White HL.

Arch Intern Med. 2012 Aug 13;172(15):1180-2. doi: 10.1001/archinternmed.2012.2171. No abstract available.

4.
5.
6.

Effects of simvastatin and pravastatin on peroxidation of erythrocyte plasma membrane lipids in patients with type 2 hypercholesterolemia.

Koter M, Franiak I, Broncel M, Chojnowska-Jezierska J.

Can J Physiol Pharmacol. 2003 May;81(5):485-92.

PMID:
12774855
8.

Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions.

Derks M, Abt M, Phelan M, Turnbull L, Meneses-Lorente G, Bech N, White AM, Parr G.

J Clin Pharmacol. 2010 Oct;50(10):1188-201. doi: 10.1177/0091270009358709. Epub 2010 May 20.

PMID:
20489031
10.
11.

Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.

Gentile S, Turco S, Guarino G, Sasso CF, Amodio M, Magliano P, Salvatore T, Corigliano G, Agrusta M, De Simone G, Gaeta I, Oliviero B, Torella R.

Diabetes Obes Metab. 2000 Dec;2(6):355-62.

PMID:
11225965
12.

Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.

Stender S, Schuster H, Barter P, Watkins C, Kallend D; MERCURY I Study Group.

Diabetes Obes Metab. 2005 Jul;7(4):430-8. Erratum in: Diabetes Obes Metab. 2005 Jul;7(4):460.

PMID:
15955130
13.

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.

Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, Miller E; Rosuvastatin Study Group.

Am Heart J. 2002 Dec;144(6):1036-43.

PMID:
12486428
14.

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.

Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW; Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.

Clin Ther. 2004 Sep;26(9):1388-99. Erratum in: Clin Ther. 2005 Jan;27(1):142.

PMID:
15531001
15.

Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.

Ramachandran S, Saraf S, Shetty C, Capps N, Bailey C.

Ann Clin Biochem. 2011 Jan;48(Pt 1):75-8. doi: 10.1258/acb.2010.010081. Epub 2010 Nov 29.

PMID:
21115572
16.

Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.

Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP.

Expert Opin Pharmacother. 2008 Apr;9(5):669-76. doi: 10.1517/14656566.9.5.669.

PMID:
18345946
17.

An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).

Smith DG, McBurney CR.

Pharmacoeconomics. 2003;21 Suppl 1:13-23.

PMID:
12648031
18.

Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.

Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D, Raza A; Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group.

Am Heart J. 2004 Apr;147(4):705-13.

PMID:
15077101
19.

Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.

Plans-RubiĆ³ P.

Am J Cardiovasc Drugs. 2006;6(3):177-88.

PMID:
16780391
20.

Comparison of efficacy, safety, and cost-effectiveness of various statins in dyslipidemic diabetic patients.

Bener A, Dogan M, Barakat L, Al-Hamaq AO.

Indian J Pharmacol. 2014 Jan-Feb;46(1):88-93. doi: 10.4103/0253-7613.125184.

Supplemental Content

Support Center